Antibody fragments: Prolonging circulation half-life special issue-antibody research — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Antibody fragments: Prolonging circulation half-life special issue-antibody research
UCL School of Pharmacy, University College London, London, UK
,
UCL School of Pharmacy, University College London, London, UK
,
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS, Foundation Trust and UCL Institute of Ophthalmology, London, UK
,
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS, Foundation Trust and UCL Institute of Ophthalmology, London, UK
1 UCL School of Pharmacy, University College London, London, UK
2 UCL School of Pharmacy, University College London, London, UK
3 National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS, Foundation Trust and UCL Institute of Ophthalmology, London, UK
4 National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS, Foundation Trust and UCL Institute of Ophthalmology, London, UK
Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over thirty-five antibody-based medicines approved for human therapy. Many more antibody and antibody-like fragments are being evaluated clinically. Production of antibody fragments can be efficient and their compact size can allows for better tissue extravasation into solid tumors than full antibodies. Unfortunately, a key limitation of antibody fragments for systemic use is their short half-life in circulation. Prolonging their circulation half-life can be accomplished clinically by the covalent conjugation of the antibody fragment to the water-soluble polymer, poly(ethylene glycol) (PEG). Many polymers and strategies are also being pursued to increase antibody fragment half-life.
Hudson, P.J. and Souriau, C. (2003) Engineered antibodies. Nature Medicine, 9, 129-134. doi:10.1038/nm0103-129
Chapman, A.P., et al. (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnology, 17, 780-783. doi:10.1038/11717
Bradbury, A., et al. (2003) Antibodies in proteomics I: Generating antibodies. Trends in Biotechnology, 21, 275281. doi:10.1016/S0167-7799(03)00112-4
Holliger, P. and Hudson, P.J. (2005) Engineered antibody fragments and the rise of single domains. Nature Biotechnology, 23, 1126-1136. doi:10.1038/nbt1142
Chowdhury, P.S. and Wu, H. (2005) Tailor-made antibody therapeutics. Methods, 36, 11-24. doi:10.1016/j.ymeth.2005.01.002
Pucca, M.B., et al. (2011) Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. Brazilian Journal of Pharmaceutical Sciences, 47, 31-38. doi:10.1590/S1984-82502011000100005
Teicher, B.A. and Chari, R.V. (2011) Antibody conjugate therapeutics: Challenges and potential. Clinical Cancer Research, 17, 6389-6397. doi:10.1158/1078-0432.CCR-11-1417
Nelson, A.L. and Reichert, J.M. (2009) Development trends for therapeutic antibody fragments. Nature Biotechnology, 27, 331-337. doi:10.1038/nbt0409-331
Kaur, S., et al. (2012) Recent trends in antibody-based oncologic imaging. Cancer Letters, 315, 97-111. doi:10.1016/j.canlet.2011.10.017
Leader, B., et al. (2008) Protein therapeutics: A summary and pharmacological classification. Nature Reviews Drug Discovery, 7, 21-39. doi:10.1038/nrd2399
Wang, W., et al. (2008) Monoclonal antibody pharmacokinetics and pharmaco-dynamics. Clinical Pharmacology & Therapeutics, 84, 548-558. doi:10.1038/clpt.2008.170
Steinwand, M., et al. (2010) Production of antibody fragments in the gram-positive bacterium Bacillus megaterium. In: Kontermann, R. and Dübel, S., Eds., Antibody Engineering, Springer Berlin Heidelberg, Berlin, Heidelberg, 293-299.
Reilly, D. and Yansura, D. (2010) Production of antibodies and antibody fragments in Escherichia coli. In: Kontermann, R. and Dübel, S., Eds., Antibody Engineering, Springer Berlin Heidelberg, Berlin, Heidelberg, 331-344.
Kunert, R. (2008) Expression of Fab fragments in CHO and Pichia pastoris. BioProcess International.
Zhao, Y., et al. (2009) Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: Papain digestion of mAb and transient expression in mammalian cells. Protein Expression and Purification, 67, 182-189. doi:10.1016/j.pep.2009.04.012
Griep, R. and McDougall, J. (2010) Analysis and purification of antibody fragments using protein A, protein G, and protein L. In: Kontermann, R. and Dübel, S., Eds., Antibody Engineering, Springer Berlin Heidelberg, Berlin, Heidelberg, 301-315.
Weir, A.N., et al. (2002) Formatting antibody fragments to mediate specific therapeutic functions. Biochemical Society Transactions, 30, 512-516. doi:10.1042/BST0300512
Singh, G. (2009) The emergence of antibody fragments and derivatives. Innovation in Pharmaceutical Tachnology, BioPharma UK, Biopharma.
Adams, G.P., et al. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Research, 61, 4750-4755.
Ahmad, Z.A., et al. (2012) scFv antibody: Principles and clinical application. Clinical and Developmental Immunology, 2012, Article ID: 980250. doi:10.1155/2012/980250
Joosten, V., et al. (2003) The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microbial Cell Factories, 2, 1. doi:10.1186/1475-2859-2-1
Hellwig, S. and Melmer, G. (2010) Bioreactor production of scFv fragments in Pichia pastoris. In: Kontermann, R. and Dübel, S., Eds., Antibody Engineering, Springer Berlin Heidelberg, Berlin, Heidelberg, 363-375.
Conrad, U. and Floss, D. (2001) Expression of antibody fragments in transgenic plants. In: Kontermann, R. and Dübel, S., Eds., Antibody Engineering, Springer Berlin Heidelberg, Berlin, Heidelberg, 377-386.
Chames, P., et al. (2009) Therapeutic antibodies: Successes, limitations and hopes for the future. British Journal of Pharmacology, 157, 220-233. doi:10.1111/j.1476-5381.2009.00190.x
Jain, M., et al. (2007) Engineering antibodies for clinical applications. Trends in Biotechnology, 25, 307-316. doi:10.1016/j.tibtech.2007.05.001
Andersen, J.T. and Sandlie, I. (2009) The versatile MHC class I: Related FcRn protects IgG and albumin from degradation. Drug Metabolism and Pharmacokinetics, 24, 318-332. doi:10.2133/dmpk.24.318
Mueller, D., et al. (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. The Journal of Biological Chemistry, 282, 12650-12660. doi:10.1074/jbc.M700820200
Nguyen, A., et al. (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Engineering Design & Selection, 19, 291-297. doi:10.1093/protein/gzl011
Pluckthun, A. and Pack, P. (1997) New protein engineering approaches to multi-valent and bispecific antibody fragments. Immunotechnology, 3, 83-105. doi:10.1016/S1380-2933(97)00067-5
Haraldsson, B. et al. (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiological Reviews, 88, 451-487. doi:10.1152/physrev.00055.2006
Chapman, A.P. (2002) PEGylated antibodies and antibody fragments for improved therapy: A review. Advanced Drug Delivery Reviews, 54, 531-545. doi:10.1016/S0169-409X(02)00026-1
Jevsevar, S., et al. (2010) PEGylation of therapeutic proteins. Biotechnology Journal, 5, 113-128. doi:10.1002/biot.200900218
Bailon, P. and Won, C.Y. (2009) PEG-modified biopharmaceuticals. Expert Opinion on Drug Delivery, 6, 1-16. doi:10.1517/17425240802650568
Chen, C., et al. (2011) Modulating antibody pharmacokinetics using hydrophilic polymers. Expert Opinion on Drug Delivery, 8, 1221-1236. doi:10.1517/17425247.2011.602399
Palm, T. et al. (2011) The effect of PEGylation on the stability of small therapeutic proteins. Pharmaceutical Development and Technology, 16, 441-448. doi:10.3109/10837450.2010.535830
Payne, R.W., et al. (2011) Product development issues for PEGylated proteins. Pharmaceutical Development Technology, 16, 423-440. doi:10.3109/10837450.2010.513990
Germershaus, O., et al. (2006) Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. Bioconjugate Chemistry, 17, 1190-1199. doi:10.1021/bc0601119
Pasut, G. and Veronese, F.M. (2012) State of the art in PEGylation: The great versatility achieved after forty years of research. Journal of Controlled Release, 161, 461-472. doi:10.1016/j.jconrel.2011.10.037
Delgado, C., et al. (1996) Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab’ fragment by poly(ethylene glycol) (PEG) modification. British Journal Cancer, 73, 175-182. doi:10.1038/bjc.1996.32
Koumenis, I.L., et al. (2000) Modulating pharmacokinetics of an anti-interleukin-8 F(ab’)2 by amine-specific PEGylation with preserved bioactivity. International Journal of Pharmaceutics, 198, 83-95. doi:10.1016/S0378-5173(99)00458-5
Li, L., et al. (2006) Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjugate Chemistry, 17, 68-76. doi:10.1021/bc0502614
Lee, L.S., et al. (1999) Prolonged circulating lives of single-chain fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjugate Chemistry, 10, 973-981.
Lu, Y., et al. (2008) Effect of PEGylation on the solution conformation of antibody fragments. Journal of Pharmaceutical Sciences, 97, 2062-2079. doi:10.1002/jps.21170
Natarajan, A., et al. (2005) Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjugate Chemistry, 16, 113-121.
Krinner, E.M., et al. (2006) A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Engineering Design & Selection, 19, 461-470. doi:10.1093/protein/gzl031
Xiong, C.Y., et al. (2006) Development of tumor targeting anti-MUC-1 multimer: Effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. Protein Engineering Design & Selection, 19, 359-367. doi:10.1093/protein/gzl020
Yang, K., et al. (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Engineering Design & Selection, 16, 761-770. doi:10.1093/protein/gzg093
Kubetzko, S., et al. (2006) PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: Effects on tumor targeting. The Journal of Biological Chemistry, 281, 35186-35201. doi:10.1074/jbc.M604127200
Humphreys, D.P., et al. (2007) Alternative antibody Fab’ fragment PEGylation strategies: Combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Engineering Design & Selection, 20, 227-234.
Albrecht, H., et al. (2003) Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconjugate Chemistry, 15, 16-26.
Knight, D.M., et al. (2004) Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by sitespecific pegylation. Platelets, 15, 409-418. doi:10.1080/09537100410001723135
Roberts, M.J., Bentley, M.D. and Harris, J.M. (2002) Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews, 54, 459-476. doi:10.1016/S0169-409X(02)00022-4
Choy, E.H.S., et al. (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology, 41, 1133-1137.
Schreiber, S., et al. (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology, 129, 807-818. doi:10.1053/j.gastro.2005.06.064
Nesbitt, A., Stephens, S., et al. (2009) Certolizumab pegol: A PEGylated anti-tumour necrosis factor alpha biological agent. In: Veronese, F., Ed., PEGylated Protein Drugs: Basic Science and Clinical Applications, Birkhäuser Basel, Basel, 229-254. doi:10.1007/978-3-7643-8679-5_14
Ton, N.C., et al. (2007) Phase I evaluation of CDP791, a PEGylated di-Fab’ conjugate that binds vascular endothelial growth factor receptor 2. Clinical Cancer Research, 13, 7113-7188. doi:10.1158/1078-0432.CCR-07-1550
Dunlap, L. (2013) The role of CD40L in ALS. Drug Discovery News, 9, 5. http://www.drugdiscoverynews.com
Mross K., F.R., Richly, H., Scharr, D., Buechert, M., Stern, A., Hoth, D., Gille, H., Audoly, L.P. and Scheulen M.E. (2011) First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study. American Association for Cancer Research, 10, A212. doi:10.1158/1535-7163.TARG-11-A212
Tolcher, A.W., et al. (2011) Phase i and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clinical Cancer Research, 17, 363-371.
Shaunak, S., et al. (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nature Chemical Biology, 2, 312-313. doi:10.1038/nchembio786
Khalili, H., et al. (2012) Comparative binding of disulfide-bridged PEG-Fabs. Bioconjugate Chemistry, 23, 22622277. doi:10.1021/bc300372r
Cong, Y., et al. (2012) Site-specific PEGylation at histidine tags. Bioconjugate Chemistry, 23, 248-63. doi:10.1021/bc200530x
Thom, J., et al. (2011) Recombinant protein hydrazides: Application to site-specific protein PEGylation. Bioconjugate Chemistry, 22, 1017-1020.
Almac Group Ltd. (2013) Almac protein conjugation technology. https://www.almacgroup.com
Gregoriadis, G., et al. (2005) Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids. International Journal of Pharmaceutics, 300, 125130.
Constantinou, A., et al. (2009) Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjugate Chemistry, 20, 924-931. doi:10.1021/bc8005122
Constantinou, A., et al. (2008) Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjugate Chemistry, 19, 643-650. doi:10.1021/bc700319r
Kopecek, J. and Kopecková, P. (2010) HPMA copolymers: Origins, early developments, present, and future. Advanced Drug Delivery Reviews, 62, 122-149. doi:10.1016/j.addr.2009.10.004
Seymour, L.W., et al. (1991) Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumourtargeted drug delivery. Selective Cancer Therapeutics, 7, 59-73. doi:10.1089/sct.1991.7.59
Lu, Z.R., et al. (1999) Polymerizable Fab’ antibody fragments for targeting of anticancer drugs. Nature Biotechnol, 17, 1101-1104. doi:10.1038/15085
Mehvar, R. (2000) Dextrans for targeted and sustained delivery of therapeutic and imaging agents. Journal of Controlled Release, 69, 1-25. doi:10.1016/S0168-3659(00)00302-3
Fagnani, R., et al. (1995) Altered pharmacokinetic and tumour localization properties of Fab’ fragments of a murine monoclonal anti-CEA antibody by covalent modification with low molecular weight dextran. Nuclear Medicine Communications, 16, 362-369. doi:10.1097/00006231-199505000-00008
Kratz, F. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal Controlled Release, 132, 171-183. doi:10.1016/j.jconrel.2008.05.010
Dennis, M.S., et al. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. The Journal of Biological Chemistry, 277, 35035-35043. doi:10.1074/jbc.M205854200
Dennis, M.S., et al. (2007) Imaging tumors with an albumin-binding Fab: A novel tumor-targeting agent. Cancer Research, 67, 254-261. doi:10.1158/0008-5472.CAN-06-2531
Smith, B.J., et al. (2001) Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjugate Chemistry, 12, 750-756. doi:10.1021/bc010003g
Walsh, G. and Jefferis, R. (2006) Post-translational modifications in the context of therapeutic proteins. Nature Biotechnology, 24, 1241-1252. doi:10.1038/nbt1252
Elliott, S., et al. (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nature Biotechnology, 21, 414-421. doi:10.1038/nbt799
Stork, R., et al. (2008) N-glycosylation as novel strategy to improve pharmaco-kinetic properties of bispecific single-chain diabodies. The Journal of Biological Chemistry, 283, 7804-7812. doi:10.1074/jbc.M709179200
Schlapschy, M., et al. (2007) Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: Effects on biophysical prop-erties and prolonged plasma half-life. Protein Engineering Design & Selection, 20, 273-284. doi:10.1093/protein/gzm020
Constantinou, A. (2005) Production and study of polysialylated antibodies for improved cancer therapy. PhD, Imperial College, London.
Brenner, M.B., et al. (1985) Cross-linking of human T cell receptor proteins: Association between the T cell idiotype β subunit and the T3 glycoprotein heavy subunit. Cell, 40, 183-190. doi:10.1016/0092-8674(85)90321-6
Glennie, M.J., et al. (1987) Preparation and performance of bispecific F(ab’ gamma)2 antibody containing thioether-linked Fab’ gamma fragments. The Journal of Immunology, 139, 2367-2375.
Shalaby, M.R., et al. (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. The Journal of Experimental Medicine, 175, 217225. doi:10.1084/jem.175.1.217
Presta, L. (2003) Anti-body engineering for therapeutics. Current Opinion in Structural Biology, 13, 519-525. doi:10.1016/S0959-440X(03)00103-9
Chames, P. and Baty, D. (2009) Bispecific antibodies for cancer therapy: The light at the end of the tunnel? Multi-Agent-Based Simulation, 1, 539-547. doi:10.4161/mabs.1.6.10015
Linke, R., et al. (2010) Catumaxomab: Clinical development and future directions. Multi-Agent-Based Simulation, 2, 129-136. doi:10.4161/mabs.2.2.11221
Kontermann, R. (2011) Bispecific antibodies: Developments and current perspectives. In: Kontermann, R.E., Ed., Bispecific Antibodies. Springer Berlin Heidelberg, Berlin, Heidelberg, 1-28. doi:10.1007/978-3-642-20910-9_1
Spencer-Green, G. (2000) Etanercept (enbrel): Update on therapeutic use. Annals Rheumatic Diseases, 59, i46-i49. doi:10.1136/ard.59.suppl_1.i46
Korhonen, R. and Moilanen, E. (2009) Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic & Clinical Pharmacology & Toxicology, 104, 276-284. doi:10.1111/j.1742-7843.2009.00375.x
Hopp, J., et al. (2010) The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Engineering Design & Selection, 23, 827-834. doi:10.1093/protein/gzq058
Peng, L.S., et al. (2001) Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). Journal of Interferon & Cytokine Research, 21, 709-720. doi:10.1089/107999001753124444